Economic impact of tobramycin in patients with cystic fibrosis in a managed care population
Wertz DA, Chang CL, Stephenson JJ, Zhang J, Kuhn RJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.3111/13696998.2011.621004

Original Paper URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Tobramycin; Cystic Fibrosis; Humans; Cost-Benefit Analysis; Administration, Inhalation; Pseudomonas aeruginosa

AccessionNumber
22012000149

Date bibliographic record published
23/03/2012